Related Experiment Video

Updated: Jan 6, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.1K

Treatment Patterns and Healthcare Resource Utilization Among Patients with Obstructive Hypertrophic Cardiomyopathy in

Yuika Ikeda1, Bruno Casaes Teixeira2, Aman Malhi2

  • 1Bristol Myers Squibb, 2-1, Otemachi 1-chome, Chiyoda-ku, Tokyo, 100-0004, Japan. yuika.ikeda@bms.com.

Cardiology and Therapy
|October 11, 2025
PubMed

Insights

Real-world data show beta-blockers were the primary treatment for obstructive hypertrophic cardiomyopathy (HCM) in Japan. Sodium channel blockers had high discontinuation and dose reduction rates, indicating a need for optimized obstructive HCM management strategies.

Area of Science:

  • Cardiology
  • Pharmacology
  • Real-world evidence

Background:

  • Obstructive hypertrophic cardiomyopathy (HCM) poses significant risks for cardiac complications and long-term outcomes.
  • Limited real-world data exist on the current management of obstructive HCM, particularly in Japan.
  • Understanding treatment patterns and healthcare resource utilization is crucial for optimizing patient care.

Purpose of the Study:

  • To evaluate pharmacological treatment patterns in patients with obstructive HCM in Japan.
  • To assess the incidence of nonpharmacological interventions for obstructive HCM.
  • To analyze healthcare resource utilization associated with obstructive HCM management.

Main Methods:

  • Retrospective longitudinal study utilizing Japanese insurance claims data from April 2014 to December 2022.
  • Analysis included medication changes (beta-blockers, non-dihydropyridine calcium channel blockers, sodium channel blockers), nonpharmacological interventions, and healthcare resource utilization.
  • A cohort of 403 patients with obstructive HCM was identified.

Main Results:

  • Beta-blockers (BBs) were the most common initial medication (74.19%).
  • Sodium channel blockers (SCBs) showed high discontinuation (22%) and dose reduction (22.2%) rates within 12 months.
  • Nonpharmacological interventions included pacemaker implantation (2.0 events/100 person-years) and septal ablation (2.0 events/100 person-years).

Conclusions:

  • Current obstructive HCM management in Japan relies heavily on beta-blockers.
  • High discontinuation and dose reduction rates for sodium channel blockers suggest potential challenges with this treatment.
  • Findings provide insights for future research to optimize obstructive HCM treatment strategies.
Abstract

Keywords:
Claims database studyDose distributionHealthcare resource utilizationHypertrophic cardiomyopathyJapanObstructive hypertrophic cardiomyopathyTreatment patternsTreatment sequence

More Related Videos

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.5K
Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples14:39

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

17.8K

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
354
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
305
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
427
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
248
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
417
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
261